PT  - JOURNAL ARTICLE
AU  - Havlucu, Yavuz
AU  - Kurhan, Fikret
AU  - Pirildar, Timur
AU  - Goktalay, Tugba
AU  - Sakar Coskun, Aysin
AU  - Celik, Pinar
AU  - Yorgancioglu, Arzu
TI  - Pulmonary infections in patients receiving treatment of tumor necrosis factor alpha antagonists
AID  - 10.1183/13993003.congress-2015.PA2647
DP  - 2015 Sep 01
TA  - European Respiratory Journal
PG  - PA2647
VI  - 46
IP  - suppl 59
4099  - http://erj.ersjournals.com/content/46/suppl_59/PA2647.short
4100  - http://erj.ersjournals.com/content/46/suppl_59/PA2647.full
SO  - Eur Respir J2015 Sep 01; 46
AB  - ITNF-α plays a critical role in host defenses against bacterial and particularly myobacterial infections. Anti TNF-α theraphy has been used for the treatment of inflammatory diseases. Aim of this study was to assess the pulmonary infections in patients receiving anti TNF-α treatment.The data files of patients who admitted to approval for the TNF-α inhibitors treatment, were retrospectively evaluated between 2008-2014.997 patients were followed in our department during this period. 421 (42,2%) patients were male and mean age was 43,1±15,8 years. Bacterial pneumonia was seen in 35 patients candiadal pneumonia was seen in 4 patients, parasitic infection was seen in 9 patients and additionally 2 patients had pneumocystis jirovecii infection. 17 patients developed tubercolosis. Culture positive pulmonary tuberculosis occured in 9 patients, 8 patients developed extrapulmonary tuberculosis (4 tuberculosis lymphadenitis, 2 tuberculous pleurisy, 1 urogenital tuberculosis, 1 skin tuberculosis). All of patients developed tuberculosis INH prophylaxis. 59 patients of 67 patients developed infections were also using other immunosuppresive treatment with TNF-α inhibitors.Tuberculosis and pulmonary infections other than tuberculosis risk increased in patients receiving TNF-α inhibitors theraphy. The clinicians must be careful in terms of pulmonary infections other than tuberculosis in these patients.